NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR) from its SEC filings: 2025 revenue $55.2 million (-44% vs the year before), net margin -297%, free cash flow -$208.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $55.2 million |
| Revenue growth | -44% |
| Net income | -$164.0 million |
| Net margin | -296.9% |
| Free cash flow | -$208.7 million |
| Diluted EPS | $-9.73 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -9% |
| Cash | $39.3 million |
| Long-term debt | $133.5 million |
| Share count, 1 year | +80% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.